Baxter and Halozyme have received approval from the US Food and Drug Administration (FDA) for Hyqvia to treat adult patients with primary immunodeficiency (PI).

Hyqvia is a combination of Immune Globulin Infusion 10% (Human) (IG 10%) and Recombinant Human Hyaluronidase. It is also the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month and one injection site per infusion to deliver a full therapeutic dose of IG.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
"The availability of HYQVIA has a significant impact on the treatment of PI."

Baxter BioScience president Ludwig Hantson said: "The availability of HYQVIA has a significant impact on the treatment of PI, allowing for effective delivery of a full therapeutic dose of IG less frequently than other subcutaneous treatments (up to once a month), while maintaining the efficacy, safety and tolerability profile that is most important for patients."

Currently, most of the patients with PI receive intravenous infusions in a doctor’s office or infusion center, and the existing subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment.

Halozyme president and CEO Helen Torley said: "Today’s FDA approval of HYQVIA is a significant milestone for Halozyme as it represents the first US approved Biologics License Application which utilizes our rHuPH20 platform."

Baxter plans to introduce Hyqvia in the US in the coming weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2013, Hyqvia has secured approval in Europe to treat adults with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections.

At present, the drug is being prescribed in different European countries such as Germany, Netherlands, Sweden, Norway, Denmark, Ireland and Italy.